HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
MDL 73811
structure given in first source; RN given refers to (Z)-isomer
Also Known As:
5'-(((Z)-4-amino-2-butenyl)methylamino)-5'-deoxyadenosine; 5'-((-4-amino-2-butenyl)methylamino)-5'-deoxyadenosine; AbeAdo; MDL-73811; Adenosine, 5'-(((2Z)-4-amino-2-buten-1-yl)methylamino)-5'-deoxy-
Networked:
5
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Purines: 651
Purine Nucleosides: 360
Adenosine: 12431
Deoxyadenosines: 1
MDL 73811: 5
Nucleic Acids, Nucleotides, and Nucleosides: 1
Nucleosides: 6847
Purine Nucleosides: 360
Adenosine: 12431
Deoxyadenosines: 1
MDL 73811: 5
Deoxyribonucleosides: 34
Deoxyadenosines: 1
MDL 73811: 5
Related Diseases
1.
Infections
08/01/1990 - "
brucei-infected mice with MDL 73811 (20 mg/kg of body weight intraperitoneally twice daily for 4 days) resulted in cures of the trypanosome infections.
"
08/01/1990 - "
brucei rhodesiense infections in mice were cured by either a combination of MDL 73811 (50 mg/kg intraperitoneally three times per day for 5 days) and relatively low oral doses of alpha-difluoromethylornithine or MDL 73811 (50 mg/kg per day for 7 days) administered alone in implanted miniosmotic pumps.
"
07/01/1997 - "
The agents studied are curative for African trypanosomiasis infections, either clinically (DFMO) or in model infections (MDL 73811, sinefungin) and thus highlight interference with AdoMet metabolism and methylation reactions as biochemical consequences of these agents.
"
03/01/1991 - "
We reported recently that administration of ([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine (MDL 73811), an enzyme-activated irreversible inhibitor of S-adenosyl-L-methionine decarboxylase (AdoMetDC; EC 4.1.1.50), a key enzyme in the synthesis of spermidine, cures African trypanosome infections in mice.
"
2.
African Trypanosomiasis (Nagana)
08/01/1990 - "
These data suggest that MDL 73811 and, perhaps, other inhibitors of AdoMet DC have potential for therapeutic use in various forms of African trypanosomiasis.
"
07/01/1997 - "
The agents studied are curative for African trypanosomiasis infections, either clinically (DFMO) or in model infections (MDL 73811, sinefungin) and thus highlight interference with AdoMet metabolism and methylation reactions as biochemical consequences of these agents.
"
3.
Ovarian Neoplasms (Ovarian Cancer)
01/01/1997 - "
By combining a novel inhibitor of ODC, such as (2R, 5R)-6-heptyne-2,5-diamine (MDL 72.175, MAP), with an inhibitor of S-adenosylmethionine decarboxylase (SAMDC), such as 5'-[[(Z)-4-aminobut-2-enyl]methylamino]-5'-deoxyadenosine (MDL 73.811, AbeAdo), spermine was selectively depleted in a human ovarian cancer cell line OVCAR-3 (i.e.
"
4.
Leukemia L1210
06/15/1993 - "
Treatment of mouse L1210 leukemia cells with (Z)-AbeAdo resulted in a total inhibition of their AdoMetDC activity followed by depletion of the spermidine and spermine content.
"
5.
Body Weight (Weight, Body)
08/01/1990 - "
brucei-infected mice with MDL 73811 (20 mg/kg of body weight intraperitoneally twice daily for 4 days) resulted in cures of the trypanosome infections.
"
Related Drugs and Biologics
1.
Eflornithine (Ornidyl)
2.
S-Adenosylmethionine (Ademetionine)
3.
Spermine
4.
Spermidine
5.
2'-deoxyadenosine
6.
Therapeutic Uses
7.
Adenosylmethionine Decarboxylase
8.
Enzymes
9.
Carboxy-Lyases
10.
sinefungin